Axa S.A. Buys 31,532 Shares of Sotera Health (NASDAQ:SHC)

AXA S.A. lifted its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 17.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 215,629 shares of the company's stock after acquiring an additional 31,532 shares during the quarter. AXA S.A. owned 0.08% of Sotera Health worth $2,950,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SHC. Blue Trust Inc. grew its position in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after acquiring an additional 1,140 shares during the period. Quarry LP purchased a new position in Sotera Health in the fourth quarter valued at approximately $28,000. GAMMA Investing LLC grew its holdings in Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock valued at $56,000 after purchasing an additional 1,121 shares during the period. Tower Research Capital LLC TRC increased its position in Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after buying an additional 1,640 shares during the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Sotera Health by 58.5% in the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company's stock valued at $124,000 after buying an additional 3,331 shares during the period. 91.03% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on SHC shares. Piper Sandler cut their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Barclays cut their target price on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and boosted their price target for the company from $14.00 to $17.00 in a research report on Monday, May 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $15.80.

Sotera Health Price Performance

NASDAQ:SHC traded down $0.06 during trading hours on Tuesday, hitting $13.44. The stock had a trading volume of 319,314 shares, compared to its average volume of 1,192,470. The company has a 50 day simple moving average of $11.48 and a two-hundred day simple moving average of $12.90. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 53.76 and a beta of 1.88. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a one year low of $9.53 and a one year high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. During the same quarter last year, the business posted $0.13 earnings per share. The firm's revenue was up 2.6% compared to the same quarter last year. Research analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.